LncRNA MALAT1 Modulates Oxaliplatin Resistance of Gastric Cancer Via Sponging MiR-22-3p

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2020 Feb 28

PMID 32104001

Citations 37

Authors

Zhenming Zhang

Ming Li

Zhitao Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: Various regulatory mechanisms have been demonstrated to be associated with cancer progression. ncRNA and mRNA play important roles in gastric cancer (GC) cell growth and drug resistance, respectively. However, the regulatory network of ncRNA and mRNA in GC oxaliplatin (OXA) resistance has not been fully clarified.

Methods: The expression of miR-22-3p, MALAT1, and zinc finger protein 91 (ZFP91) was detected in tissues and cells using quantitative real-time PCR. The protein level of ZFP91 was measured by Western blot analysis. Luciferase reporter, pull-down, and RNA immunoprecipitation assays were used to determine the relationship between MALAT1, miR-22-3p, and ZFP91. MTT assay was applied to measure cell survival and proliferation. Cell apoptosis was detected using flow cytometry. Tumor xenograft assay was used to detect the function of miR-22-3p in vivo.

Results: In this study, we found that MALAT1 and ZFP91 expression was upregulated while the expression of miR-22-3p was downregulated in GC/OXA tissues and cells. Additionally, miR-22-3p was a target miRNA of MALAT1 and ZFP91 was a target mRNA of miR-22-3p. Functional studies showed that the knockdown of MALAT1 or overexpression of miR-22-3p inhibited GC/OXA cell survival, proliferation, and drug resistance as well as induced apoptosis, which could be reversed by the inhibition of miR-22-3p or overexpression of ZFP91.

Conclusion: We observed a new regulatory network for MALAT1 in drug resistance of GC. MALAT1 modulates ZFP91 to promote GC cells OXA resistance via sponging miR-22-3p.

Citing Articles

Targeting STK26 and ATG4B: miR-22-3p as a modulator of autophagy and tumor progression in HCC.

Li K, Bai Y, Wang J, Ren L, Mo A, Liu R Transl Oncol. 2024; 51:102214.

PMID: 39608212 PMC: 11635773. DOI: 10.1016/j.tranon.2024.102214.

Oxaliplatin activates P53/miR-34a/survivin axis in inhibiting the progression of gastric cancer cells.

Guo Q, Wang X, Zhai Y, Dong Y, He Q Immun Inflamm Dis. 2024; 12(9):e70004.

PMID: 39254476 PMC: 11386343. DOI: 10.1002/iid3.70004.

P53-associated lncRNAs regulate immune functions and RNA-modifiers in gastric cancer.

Huanjie Z, Bukhari I, Fazhan L, Wen H, Wang J, Wanqing W Heliyon. 2024; 10(15):e35228.

PMID: 39166030 PMC: 11334848. DOI: 10.1016/j.heliyon.2024.e35228.

LncRNA MALAT1 Knockdown Alleviates Fibrogenic Response in Human Endometrial Stromal Cells Via the miR-22-3p/TGFβR1/Smad2/3 Pathway.

Zhu Z, Huang Y, Song Y, Lu J, Hu L, Chen X Cell Biochem Biophys. 2024; 82(4):3573-3584.

PMID: 39154131 DOI: 10.1007/s12013-024-01445-z.

Unraveling the role of long non-coding RNAs in therapeutic resistance in acute myeloid leukemia: New prospects & challenges.

Sharma S Noncoding RNA Res. 2024; 9(4):1203-1221.

PMID: 39036603 PMC: 11259994. DOI: 10.1016/j.ncrna.2024.05.009.

References

Xu S, Zhu S, Wang Y, Huang J, Chen M, Wu Q . ECD promotes gastric cancer metastasis by blocking E3 ligase ZFP91-mediated hnRNP F ubiquitination and degradation. Cell Death Dis. 2018; 9(5):479. PMC: 5924763. DOI: 10.1038/s41419-018-0525-x. View

Li J, Zhang Y, Zhao J, Kong F, Chen Y . Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells. Mol Cell Biochem. 2011; 357(1-2):31-8. DOI: 10.1007/s11010-011-0872-8. View

Ying L, Chen Q, Wang Y, Zhou Z, Huang Y, Qiu F . Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol Biosyst. 2012; 8(9):2289-94. DOI: 10.1039/c2mb25070e. View

Shi S, Wang L, Yu B, Li Y, Jin Y, Bai X . LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget. 2015; 6(13):11652-63. PMC: 4484483. DOI: 10.18632/oncotarget.3457. View

Qi Y, Ooi H, Wu J, Chen J, Zhang X, Tan S . MALAT1 long ncRNA promotes gastric cancer metastasis by suppressing PCDH10. Oncotarget. 2016; 7(11):12693-703. PMC: 4914315. DOI: 10.18632/oncotarget.7281. View

YiRen H, Yingcong Y, Sunwu Y, Keqin L, Xiaochun T, Senrui C . Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer. 2017; 16(1):174. PMC: 5699172. DOI: 10.1186/s12943-017-0743-3. View

Li L, Zhang L, Zhang Y, Zhou F . Increased expression of LncRNA BANCR is associated with clinical progression and poor prognosis in gastric cancer. Biomed Pharmacother. 2015; 72:109-12. DOI: 10.1016/j.biopha.2015.04.007. View

Zhu N, Zhang D, Xie H, Zhou Z, Chen H, Hu T . Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2. Mol Cell Biochem. 2011; 351(1-2):157-64. DOI: 10.1007/s11010-011-0723-7. View

Peng Y, Shen X, Jiang H, Chen Z, Wu J, Zhu Y . miR-188-5p Suppresses Gastric Cancer Cell Proliferation and Invasion via Targeting ZFP91. Oncol Res. 2018; 27(1):65-71. PMC: 7848256. DOI: 10.3727/096504018X15191223015016. View

10.

Karreth F, Pandolfi P . ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov. 2013; 3(10):1113-21. PMC: 3801300. DOI: 10.1158/2159-8290.CD-13-0202. View

11.

Zuo Q, Cao L, Yu T, Gong L, Wang L, Zhao Y . MicroRNA-22 inhibits tumor growth and metastasis in gastric cancer by directly targeting MMP14 and Snail. Cell Death Dis. 2015; 6:e2000. PMC: 4670920. DOI: 10.1038/cddis.2015.297. View

12.

Yan J, Dang Y, Liu S, Zhang Y, Zhang G . LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes. Tumour Biol. 2016; 37:16345–16355. DOI: 10.1007/s13277-016-5448-5. View

13.

Chou J, Wang B, Zheng T, Li X, Zheng L, Hu J . MALAT1 induced migration and invasion of human breast cancer cells by competitively binding miR-1 with cdc42. Biochem Biophys Res Commun. 2016; 472(1):262-9. DOI: 10.1016/j.bbrc.2016.02.102. View

14.

Nie W, Ge H, Yang X, Sun X, Huang H, Tao X . LncRNA-UCA1 exerts oncogenic functions in non-small cell lung cancer by targeting miR-193a-3p. Cancer Lett. 2015; 371(1):99-106. DOI: 10.1016/j.canlet.2015.11.024. View

15.

Cassidy J, Misset J . Oxaliplatin-related side effects: characteristics and management. Semin Oncol. 2002; 29(5 Suppl 15):11-20. DOI: 10.1053/sonc.2002.35524. View

16.

Zhang G, Li S, Lu J, Ge Y, Wang Q, Ma G . LncRNA MT1JP functions as a ceRNA in regulating FBXW7 through competitively binding to miR-92a-3p in gastric cancer. Mol Cancer. 2018; 17(1):87. PMC: 5930724. DOI: 10.1186/s12943-018-0829-6. View

17.

Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G . The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2012; 73(3):1180-9. PMC: 3589741. DOI: 10.1158/0008-5472.CAN-12-2850. View

18.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

19.

Oun R, Moussa Y, Wheate N . The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018; 47(19):6645-6653. DOI: 10.1039/c8dt00838h. View

20.

Zheng H, Shi D, Wang Y, Li X, Xu Y, Tripathi P . High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. Int J Clin Exp Pathol. 2014; 7(6):3174-81. PMC: 4097248. View